Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study).

ABSTRACT:

Background

Psoriasis imposes a significant treatment burden on patients, particularly impacting well-being and quality of life (QoL). The psychosocial impact of psoriasis treatments remains unexplored in most patient populations.

Objective

To assess the impact of adalimumab on health-related QoL (HRQoL) in Korean patients with psoriasis.

Methods

This 24-week, multicenter, observational study, assessed HRQoL in Korean patients treated with adalimumab in a real-world setting. Patient-reported outcomes (PROs) including European Quality of Life-5 Dimension scale (EQ-5D), EQ-5D VAS, SF-36, and DLQI were evaluated at week 16 and 24, versus baseline. Patient satisfaction was assessed using TSQM.

Results

Among 97 enrolled patients, 77 were assessed for treatment effect

SUBMITTER: Kim DH 

PROVIDER: S-EPMC10112372 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature